Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 1008, doi. 10.1016/j.molonc.2014.12.006
- By:
- Publication type:
- Article
Works matching IS 15747891 AND DT 2015 AND VI 9 AND IP 5
Results: 12
1
2
Biomarker validation and testing.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 960, doi. 10.1016/j.molonc.2014.10.004
- By:
- Publication type:
- Article
3
The Brave New World of clinical cancer research: Adaptive biomarker-driven trials integrating clinical practice with clinical research.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 951, doi. 10.1016/j.molonc.2015.02.011
- By:
- Publication type:
- Article
4
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 967, doi. 10.1016/j.molonc.2014.09.011
- By:
- Publication type:
- Article
5
Emerging uses of patient generated health data in clinical research.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 1018, doi. 10.1016/j.molonc.2014.08.006
- By:
- Publication type:
- Article
6
Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 1025, doi. 10.1016/j.molonc.2014.10.009
- By:
- Publication type:
- Article
7
Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting Precision Cancer Medicine to the test.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 940, doi. 10.1016/j.molonc.2014.06.014
- By:
- Publication type:
- Article
8
Assessment of benefits and risks in development of targeted therapies for cancer – The view of regulatory authorities.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 1034, doi. 10.1016/j.molonc.2014.10.003
- By:
- Publication type:
- Article
9
Early phase clinical trials to identify optimal dosing and safety.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 997, doi. 10.1016/j.molonc.2014.07.025
- By:
- Publication type:
- Article
10
Hurdles on the road to personalized medicine.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 935, doi. 10.1016/j.molonc.2014.08.009
- By:
- Publication type:
- Article
11
Innovative clinical trials for development of personalized cancer medicine.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. 933, doi. 10.1016/j.molonc.2015.02.013
- By:
- Publication type:
- Article
12
Editorial Board.
- Published in:
- Molecular Oncology, 2015, v. 9, n. 5, p. ii, doi. 10.1016/S1574-7891(15)00079-4
- Publication type:
- Article